Clovis Oncology, Inc. (CLVS) Q3 2019 Results Conference Call November 7, 2019 8:30 AM ET
Company Participants
Breanna Burkart - VP, IR
Patrick Mahaffy - President and CEO
Dan Muehl - CFO
Dr. Lindsey Rolfe - Chief Medical Officer
Conference Call Participants
Kennen MacKay - RBC Capital Markets
Tazeen Ahmad - Bank of America
Gena Wang - Barclays
Paul Choi - Goldman Sachs
Andrew Berens - SVB Leerink
Joe Catanzaro - Piper Jaffray
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Clovis Oncology Third Quarter 2019 Earnings Conference Call. At this time, all participants’ lines are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to Ms. Breanna Burkart, Vice President, Investor Relations. Please go ahead.
Breanna Burkart
Thank you, Simon. Good morning, and welcome to the Clovis Oncology third quarter 2019 conference call. Thank you for joining us.
You have likely seen this morning's news release. If not, it is available on our website at www.clovisoncology.com. As a reminder, this conference call is being recorded and webcast. Remarks may be accessed live on our website during the call and will be available on our archive for the next several weeks.
Today's agenda includes the following: Patrick Mahaffy, our President and CEO, will discuss the key components and highlights of today's corporate update; then, Dan Muehl, Clovis' Chief Financial Officer, will cover the quarter's financial results in greater detail. Patrick will make a few closing remarks, and then we'll open the call for Q&A, during which time, Dr. Lindsey Rolfe, our Chief Medical Officer, will also be available to answer questions.
Before we begin, please note that during today's conference call, we may make forward-looking statements within the meaning of the
- Read more current CLVSQ analysis and news
- View all earnings call transcripts